Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.

H Kuwayama1, M Asaka, T Sugiyama

  • 1Department of Gastroenterology and Hepatology, University Hospital at Koshigaya, Dokkyo University School of Medicine, Koshigaya, Japan.

Alimentary Pharmacology & Therapeutics
|April 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-induced osteomalacia.

QJM : monthly journal of the Association of Physicians·2022
Same author

Associations among tooth loss, systemic inflammation and antibody titers to periodontal pathogens in Japanese patients with cardiovascular disease.

Journal of periodontal research·2017
Same author

Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.

Domestic animal endocrinology·2016
Same author

Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1.

Molecular psychiatry·2016
Same author

Insulinotropic action of bombesin-like peptides mediated by gastrin-releasing peptide receptors in steers.

Journal of animal science·2016
Same author

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.

British journal of cancer·2013

Rabeprazole-based therapy effectively eradicates Helicobacter pylori, even in clarithromycin-resistant cases. This proton pump inhibitor regimen shows promise for first-line H. pylori treatment in Japan.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Pharmacology

Background:

  • Large-scale studies on rabeprazole-based Helicobacter pylori eradication therapy are lacking in Japan.
  • H. pylori infection remains a significant global health concern, necessitating effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of rabeprazole-based H. pylori eradication therapy.
  • To assess the impact of antibiotic susceptibility, CYP2C19 genotype, and drug dosages on treatment outcomes.

Main Methods:

  • A randomized controlled trial involving 479 H. pylori-positive patients with gastric or duodenal ulcers across 35 centers.
  • Patients were assigned to four groups receiving different dosages of rabeprazole and clarithromycin in combination with amoxicillin for 7 days.

Related Experiment Videos

Main Results:

  • Overall eradication rates ranged from 86% to 91% across the four treatment groups.
  • Eradication rates were high (95%) for clarithromycin-susceptible strains but significantly lower (50%) for resistant strains.
  • Eradication rates were 88% in extensive metabolizers and 96% in poor metabolizers of CYP2C19.

Conclusions:

  • Rabeprazole-based triple therapy demonstrates effectiveness, achieving 50% eradication even in clarithromycin-resistant H. pylori infections.
  • The therapy shows good efficacy in extensive metabolizers, suggesting its suitability as a first-line treatment.
  • Rabeprazole can be recommended as a component of first-line proton pump inhibitor-based triple therapy for H. pylori eradication.